EP. 1: The Targeted Pulse: Cancer Research Slowed by Funding Freezes and the FDA Takes Forward Steps
The FDA advances in multiple cancer types, and researchers assess potential impacts of funding freezes on cancer research.
March 2025 Targeted Pulse
Forward steps are being made in HNSCC, and the first patient with MDS has been treated with iadademstat/azacitidine.
This week's Targeted Pulse highlights immunotherapy’s success in triple-negative breast cancer and key FDA actions shaping treatment advancements.
Positive data and developments to be aware of in AML, breast cancer, PDAC, and NMIBC.
Survivorship Care is highlighted, providing emotional, physical, and practical care for patients, along with other positive data to be aware of.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
